Search 

leadermed Group是一家将美国正在临床阶段创新药license in China以及亚洲部分国家的公司，致力于将国外最新研究成果以最快速度让China乃至亚洲其他国家患者使用上国际最安全有效创新药，将来也将自主研发我们China人自己的创新药，为世界上所有患者服务！

Foncoo was founded in 1999, headquartered in Shenzhen, is a specialty pharmaceutical company with more than 20 years of experience focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases in China.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine. 

license-in paradigm shifting durgs to China patients

Lilly

Link Health is a leading Chinese pharmaceutical company based in Southern China, focusing on the development of innovative drugs for the unmet medical needs.
Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, favourable regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently.
The company has established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office focuses on collaborations with global pharma/biotech partners and research institutes.

A public pharmaceutical company with over 30 years history, and mainly focuses on Respiratory, Digestive and Oncology areas.

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs

Luye Pharma Group Co., Ltd. is a professional pharmaceutical enterprise built on a solid foundation of research and development and focusing on the largest and fastest growing therapeutic areas - central nervous system, oncology, cardiovascular system, and metabolism . The company was founded in 1994 and listed on the main board of the Hong Kong Stock Exchange in 2014 (02186.HK). The company has state-of-the-art production facilities located in Yantai, Nanjing, Beijing and Luzhou; as well as overseas branch offices in EU, United States, Singapore and Malaysia. The company has approximately 4,000 employees, including close to 300 R&D specialists and over 1,300 sales and marketing personnel. Luye Pharma is devoted to providing customers with high-quality innovative pharmaceutical products and professional services. The company currently sells approximately 30 products and over 80% of its total revenue is attributable to patent-protected products. Luye Pharma has an extensive sales & distribution network covering over 11,000 hospitals in 30 provinces, autonomous regions and municipalities in China, as well as exporting to many overseas countries and regions. Luye Pharma currently has 8 product candidates for overseas markets: one is preparing to submit NDA application; three are undergoing clinical trials in the US and one will start clinical trials in the US. soon.

In addition, Luye has its own biosimilar business (novel antibodies, prolia, xgeva, eylea, avastin, opdivo, trulicity, consentyx, zaltrap, CAR-T); Established in 2013, Boan Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic antibodies, which are mainly focused on key therapeutic areas such as oncology, diabetes and immunological diseases.

Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.

Mabgen Biotech is a Hengrui Group company, focusing on the CMC part of biologics development.